Asset Details
Do you wish to reserve the book?
Druggability of lipid metabolism modulation against renal fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Druggability of lipid metabolism modulation against renal fibrosis
Do you wish to request the book?
Druggability of lipid metabolism modulation against renal fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Druggability of lipid metabolism modulation against renal fibrosis
2022
Overview
Renal fibrosis contributes to progressive damage to renal structure and function. It is a common pathological process as chronic kidney disease develops into kidney failure, irrespective of diverse etiologies, and eventually leads to death. However, there are no effective drugs for renal fibrosis treatment at present. Lipid aggregation in the kidney and consequent lipotoxicity always accompany chronic kidney disease and fibrosis. Numerous studies have revealed that restoring the defective fatty acid oxidation in the kidney cells can mitigate renal fibrosis. Thus, it is an important strategy to reverse the dysfunctional lipid metabolism in the kidney, by targeting critical regulators of lipid metabolism. In this review, we highlight the potential “druggability” of lipid metabolism to ameliorate renal fibrosis and provide current pre-clinical evidence, exemplified by some representative druggable targets and several other metabolic regulators with anti-renal fibrosis roles. Then, we introduce the preliminary progress of noncoding RNAs as promising anti-renal fibrosis drug targets from the perspective of lipid metabolism. Finally, we discuss the prospects and deficiencies of drug targeting lipid reprogramming in the kidney.
Publisher
Springer Singapore,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Carnitine O-Palmitoyltransferase - metabolism
/ Epithelial Cells - pathology
/ Fibrosis
/ Lipid Metabolism - drug effects
/ Lipid Metabolism - physiology
/ Lipids
/ Peroxisome Proliferator-Activated Receptors - metabolism
/ Renal Insufficiency, Chronic - pathology
/ Review
/ RNA, Untranslated - metabolism
/ Sterol Regulatory Element Binding Proteins - metabolism
/ Structure-function relationships
/ Transforming Growth Factor beta - drug effects
/ Transforming Growth Factor beta - metabolism
/ Vaccine
